These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 37183672)

  • 41. The earlier, the better: Impact of early diagnosis on clinical outcome in idiopathic pulmonary fibrosis.
    Aiello M; Bertorelli G; Bocchino M; Chetta A; Fiore-Donati A; Fois A; Marinari S; Oggionni T; Polla B; Rosi E; Stanziola A; Varone F; Sanduzzi A
    Pulm Pharmacol Ther; 2017 Jun; 44():7-15. PubMed ID: 28257817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
    Vancheri C; Kreuter M; Richeldi L; Ryerson CJ; Valeyre D; Grutters JC; Wiebe S; Stansen W; Quaresma M; Stowasser S; Wuyts WA;
    Am J Respir Crit Care Med; 2018 Feb; 197(3):356-363. PubMed ID: 28889759
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pirfenidone for the treatment of idiopathic pulmonary fibrosis.
    Xaubet A; Serrano-Mollar A; Ancochea J
    Expert Opin Pharmacother; 2014 Feb; 15(2):275-81. PubMed ID: 24308635
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes of patients with advanced idiopathic pulmonary fibrosis treated with nintedanib or pirfenidone in a real-world multicentre cohort.
    Durheim MT; Bendstrup E; Carlson L; Sutinen EM; Hyldgaard C; Kalafatis D; Myllärniemi M; Sköld CM; Sjåheim T
    Respirology; 2021 Oct; 26(10):982-988. PubMed ID: 34291523
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacological management of IPF.
    Borie R; Justet A; Beltramo G; Manali ED; Pradère P; Spagnolo P; Crestani B
    Respirology; 2016 May; 21(4):615-25. PubMed ID: 27072575
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The therapy of idiopathic pulmonary fibrosis: what is next?
    Somogyi V; Chaudhuri N; Torrisi SE; Kahn N; Müller V; Kreuter M
    Eur Respir Rev; 2019 Sep; 28(153):. PubMed ID: 31484664
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
    Zurkova M; Kriegova E; Kolek V; Lostakova V; Sterclova M; Bartos V; Doubkova M; Binkova I; Svoboda M; Strenkova J; Janotova M; Plackova M; Lacina L; Rihak V; Petrik F; Lisa P; Bittenglova R; Tyl R; Ondrejka G; Suldova H; Lnenicka J; Psikalova J; Snizek T; Homolka J; Kralova R; Kervitzer J; Vasakova M; ;
    Respir Res; 2019 Jan; 20(1):16. PubMed ID: 30665416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
    Dorey-Stein ZL; Shapiro W; Zhao H; Cordova FC; Criner GJ; Galli JA
    Respir Med; 2021 Dec; 190():106599. PubMed ID: 34788735
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study.
    Sgalla G; Lo Greco E; Calvello M; Varone F; Iovene B; Cerri S; Donatelli P; Vancheri A; Pavone M; Luppi F; Vancheri C; Richeldi L
    Respirology; 2020 Nov; 25(11):1144-1151. PubMed ID: 32190952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: Real-world experience.
    Isshiki T; Sakamoto S; Yamasaki A; Shimizu H; Miyoshi S; Nakamura Y; Homma S; Kishi K
    Respir Med; 2021 Oct; 187():106551. PubMed ID: 34343721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nintedanib for Idiopathic Pulmonary Fibrosis.
    Tepede A; Yogaratnam D
    J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Current and novel drug therapies for idiopathic pulmonary fibrosis.
    Adamali HI; Maher TM
    Drug Des Devel Ther; 2012; 6():261-72. PubMed ID: 23055696
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pirfenidone in idiopathic pulmonary fibrosis.
    Maher TM
    Drugs Today (Barc); 2010 Jul; 46(7):473-82. PubMed ID: 20683502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis.
    Sugino K; Ono H; Watanabe N; Ando M; Tsuboi E; Homma S; Kishi K
    BMC Pulm Med; 2021 Jul; 21(1):218. PubMed ID: 34246227
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
    Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
    Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Idiopathic pulmonary fibrosis: an update.
    Spagnolo P; Sverzellati N; Rossi G; Cavazza A; Tzouvelekis A; Crestani B; Vancheri C
    Ann Med; 2015 Feb; 47(1):15-27. PubMed ID: 25613170
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).
    Iwata T; Yoshino I; Yoshida S; Ikeda N; Tsuboi M; Asato Y; Katakami N; Sakamoto K; Yamashita Y; Okami J; Mitsudomi T; Yamashita M; Yokouchi H; Okubo K; Okada M; Takenoyama M; Chida M; Tomii K; Matsuura M; Azuma A; Iwasawa T; Kuwano K; Sakai S; Hiroshima K; Fukuoka J; Yoshimura K; Tada H; Nakagawa K; Nakanishi Y;
    Respir Res; 2016 Jul; 17(1):90. PubMed ID: 27450274
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.
    Hilberg O; Simonsen U; du Bois R; Bendstrup E
    Clin Respir J; 2012 Jul; 6(3):131-43. PubMed ID: 22697264
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Administration of nintedanib after discontinuation for acute exacerbation of idiopathic pulmonary fibrosis: a case report.
    Ikeda S; Sekine A; Baba T; Yamakawa H; Morita M; Kitamura H; Ogura T
    BMC Pulm Med; 2016 Mar; 16():38. PubMed ID: 26940352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.